Log in

NASDAQ:NAVB - Navidea Biopharmaceuticals Stock Price, Forecast & News

$0.99
+0.09 (+10.00 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$0.88
Now: $0.99
$1.02
50-Day Range N/A
52-Week Range
$0.49
Now: $0.99
$4.20
Volume254,393 shs
Average Volume287,270 shs
Market Capitalization$17.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a preclinical therapeutic research collaboration with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NAVB
CUSIPN/A
CIKN/A
Phone614-793-7500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14
Market Cap$17.90 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.


Navidea Biopharmaceuticals (NASDAQ:NAVB) Frequently Asked Questions

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the NASDAQ under the ticker symbol "NAVB."

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NASDAQ:NAVB) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.17) earnings per share (EPS) for the quarter. The company had revenue of $0.24 million for the quarter. View Navidea Biopharmaceuticals' Earnings History.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Navidea Biopharmaceuticals.

What is the consensus analysts' recommendation for Navidea Biopharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Navidea Biopharmaceuticals.

Has Navidea Biopharmaceuticals been receiving favorable news coverage?

Headlines about NAVB stock have trended extremely negative on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Navidea Biopharmaceuticals earned a daily sentiment score of -4.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the near term. View News Stories for Navidea Biopharmaceuticals.

Who are some of Navidea Biopharmaceuticals' key competitors?

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include Plug Power (PLUG) and On Track Innovations (OTIV).

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the folowing people:
  • Mr. Jed A. Latkin, CEO, COO, CFO & Director (Age 45)
  • Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer (Age 51)
  • Erika Gibson, Director of Fin. & Admin.
  • Mr. William J. Regan, Chief Compliance Officer (Age 67)

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $0.99.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $17.90 million. Navidea Biopharmaceuticals employs 14 workers across the globe.View Additional Information About Navidea Biopharmaceuticals.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is http://www.navidea.com/.

How can I contact Navidea Biopharmaceuticals?

The company can be reached via phone at 614-793-7500.


MarketBeat Community Rating for Navidea Biopharmaceuticals (NASDAQ NAVB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  4 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  7
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: volatile stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel